X. Cabagnols

Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.

F. Pasquier, W. Vainchenker, I. Plo, 2014, Clinical lymphoma, myeloma & leukemia.

Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms

F. Pasquier, E. Solary, W. Vainchenker, 2020, Oncogene.

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution

E. Solary, W. Vainchenker, L. Knoops, 2014, Leukemia.

Endogenous megakaryocytic colonies underline association between megakaryocytes and calreticulin mutations in essential thrombocythemia

P. Cony-Makhoul, S. Carillo, F. Girodon, 2015, Haematologica.

A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm.

J. Cayuela, W. Vainchenker, X. Cabagnols, 2015, The New England journal of medicine.

TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis.

W. Vainchenker, O. Bernard, V. Della Valle, 2016, DNA repair.

Heterozygous and Homozygous JAK2V617F States Modeled by Induced Pluripotent Stem Cells from Myeloproliferative Neoplasm Patients

P. Opolon, Longyun Chen, E. Solary, 2013, PloS one.

Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.

W. Vainchenker, N. Debili, R. Favier, 2016, Blood.